Promising cancer-fighting tactic—using nanoparticles—runs into a potential glitch

cancerdna
Credit: Shutterstock

The challenge of chemotherapy is to kill off the tumor cells without doing too much harm to healthy ones. The inter-endothelial gaps promised a way to do that. Nanoparticles up to 300 nm in diameter can fit through the gaps, and they can’t permeate normal blood vessels the same way. So nanoparticles loaded with a drug should, it stands to reason, selectively enter and attack tumor tissue but leave healthy tissue alone. An inherently biomedical challenge was seemingly transformed into one of nanotechnology and fluid dynamics.

The mechanism of their action, however, has never been fully verified. No technique exists that can image nanoparticles in vivo, in real time, and with sufficient resolution to observe the particles slipping through the inter-endothelial gaps in a tumor’s blood vessels. The idea that they do has always been an assumption.

Related article:  ACLU to Myriad Genetics: Patients, not companies, own personal genetic data

New research by Shrey Sindhwani, Abdullah Muhammad Syed (both with Warren Chan’s laboratory at the University of Toronto), and their colleagues suggests that that assumption might not be correct. Most nanoparticles that end up in tumors, the researchers found, get there by passing through the endothelial cells, not between them.

The task of getting nanomedicines into tumors may therefore be a biological one rather than a physical one after all.

Read the original post

Outbreak
Outbreak Daily Digest
Biotech Facts & Fallacies
Talking Biotech
Genetics Unzipped
Infographic: What are mRNA COVID-19 vaccines and how do they work?

Infographic: What are mRNA COVID-19 vaccines and how do they work?

As of 1 December 2020, thirteen vaccines have reached the final stage of testing: where they are being given to ...
favicon

Environmental Working Group: EWG challenges safety of GMOs, food pesticide residues

Known by some as the "Environmental Worrying Group," EWG lobbies ...
m hansen

Michael Hansen: Architect of Consumers Union ongoing anti-GMO campaign

Michael K. Hansen (born 1956) is thought by critics to be ...
News on human & agricultural genetics and biotechnology delivered to your inbox.
glp menu logo outlined

Newsletter Subscription

Optional. Mail on special occasions.
Send this to a friend